Understanding Retinal Vasculitis Associated with Brolucizumab: Complex Pathophysiology or Occam's Razor?
作者信息
Sharma Ashish, Kumar Nilesh, Parachuri Nikulaa, Singh Sonali, Bandello Francesco, Regillo Carl D, Boyer David, Nguyen Quan Dong
机构信息
Lotus Eye Hospital and Institute, Coimbatore, India.
Ocular Pathologist, Madhavi Netralaya, Ara, India.
出版信息
Ocul Immunol Inflamm. 2022 Aug;30(6):1508-1510. doi: 10.1080/09273948.2021.1897628. Epub 2021 May 20.
Abstract
摘要
相似文献
1
Understanding Retinal Vasculitis Associated with Brolucizumab: Complex Pathophysiology or Occam's Razor?
Ocul Immunol Inflamm. 2022 Aug;30(6):1508-1510. doi: 10.1080/09273948.2021.1897628. Epub 2021 May 20.
2
[Intraocular inflammation with occlusive retinal vasculitis following intravitreal injection of brolucizumab].
Ophthalmologe. 2022 Mar;119(3):296-299. doi: 10.1007/s00347-021-01341-4. Epub 2021 Feb 24.
3
Swept-source optical coherence tomography angiography of retinal occlusive vasculitis following brolucizumab administration: a case report.
BMC Ophthalmol. 2022 Jun 3;22(1):244. doi: 10.1186/s12886-022-02465-0.
4
Expert Opinion on Management of Intraocular Inflammation, Retinal Vasculitis, and Vascular Occlusion after Brolucizumab Treatment.
Ophthalmol Retina. 2021 Jun;5(6):519-527. doi: 10.1016/j.oret.2020.09.020. Epub 2020 Sep 29.
5
Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER.
Ophthalmology. 2021 Jul;128(7):1050-1059. doi: 10.1016/j.ophtha.2020.11.011. Epub 2020 Nov 15.
6
Three cases of brolucizumab-associated retinal vasculitis treated with systemic and local steroid therapy.
Jpn J Ophthalmol. 2021 Mar;65(2):199-207. doi: 10.1007/s10384-021-00818-8. Epub 2021 Feb 5.
7
Re: Monés et al.: Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER (Ophthalmology. 2021;128:1050-1059).
Ophthalmology. 2021 Sep;128(9):e47. doi: 10.1016/j.ophtha.2021.04.029. Epub 2021 May 28.
8
Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab.
Ophthalmology. 2020 Oct;127(10):1345-1359. doi: 10.1016/j.ophtha.2020.04.017. Epub 2020 Apr 25.
9
Association of Occlusive Retinal Vasculitis With Intravitreal Faricimab.
JAMA Ophthalmol. 2024 May 1;142(5):489-491. doi: 10.1001/jamaophthalmol.2024.0928.
10
Early Experience With Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration.
JAMA Ophthalmol. 2021 Apr 1;139(4):441-448. doi: 10.1001/jamaophthalmol.2020.7085.
引用本文的文献
1
Changes in Aqueous Humor Cytokine Profile Following Intravitreal Brolucizumab Injection.
Clin Ophthalmol. 2025 Feb 11;19:427-437. doi: 10.2147/OPTH.S504956. eCollection 2025.
2
Brolucizumab versus Aflibercept in Patients with Diabetic Macular Edema: A Meta-Analysis of Randomized Controlled Trials.
Clin Ophthalmol. 2024 Dec 10;18:3679-3690. doi: 10.2147/OPTH.S487055. eCollection 2024.
3
Bilateral occlusive retinal vasculitis secondary to intravitreal faricimab injection: a case report and review of literature.
Eye Vis (Lond). 2024 Dec 3;11(1):48. doi: 10.1186/s40662-024-00416-y.
4
Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration.
Jpn J Ophthalmol. 2024 Sep;68(5):531-537. doi: 10.1007/s10384-024-01107-w. Epub 2024 Aug 20.
5
Brolucizumab-associated intraocular inflammation in Indian patients by VRSI study group.
Indian J Ophthalmol. 2024 Aug 1;72(8):1156-1161. doi: 10.4103/IJO.IJO_2973_23. Epub 2024 Jul 29.
6
Factors Associated With Intraocular Inflammation in Neovascular Age-Related Macular Degeneration Patients Treated With Brolucizumab.
Invest Ophthalmol Vis Sci. 2024 Jan 2;65(1):8. doi: 10.1167/iovs.65.1.8.
7
Beovu, but not Lucentis impairs the function of the barrier formed by retinal endothelial cells in vitro.
Sci Rep. 2022 Jul 21;12(1):12493. doi: 10.1038/s41598-022-16770-7.
8
Swept-source optical coherence tomography angiography of retinal occlusive vasculitis following brolucizumab administration: a case report.
BMC Ophthalmol. 2022 Jun 3;22(1):244. doi: 10.1186/s12886-022-02465-0.
9
Bilateral blindness after uneventful brolucizumab injection for macular degeneration.
BMC Ophthalmol. 2022 Feb 16;22(1):80. doi: 10.1186/s12886-022-02305-1.
10
Initial Pro Re Nata Brolucizumab for Exudative AMD: The PROBE Study.
J Clin Med. 2021 Sep 15;10(18):4153. doi: 10.3390/jcm10184153.
本文引用的文献
1
Brolucizumab-related retinal vasculitis with exacerbation following ranibizumab retreatment: A clinicopathologic case study.
Am J Ophthalmol Case Rep. 2020 Nov 10;20:100989. doi: 10.1016/j.ajoc.2020.100989. eCollection 2020 Dec.
2
Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER.
Ophthalmology. 2021 Jul;128(7):1050-1059. doi: 10.1016/j.ophtha.2020.11.011. Epub 2020 Nov 15.
3
Expert Opinion on Management of Intraocular Inflammation, Retinal Vasculitis, and Vascular Occlusion after Brolucizumab Treatment.
Ophthalmol Retina. 2021 Jun;5(6):519-527. doi: 10.1016/j.oret.2020.09.020. Epub 2020 Sep 29.
4
Occlusive Retinal Vasculitis Following Intravitreal Brolucizumab.
J Vitreoretin Dis. 2020 Jul;4(4):269-279. doi: 10.1177/2474126420930863. Epub 2020 Jul 1.
5
Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab.
Ophthalmology. 2020 Oct;127(10):1345-1359. doi: 10.1016/j.ophtha.2020.04.017. Epub 2020 Apr 25.
6
Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations.
Am J Ophthalmol Case Rep. 2020 Apr 2;18:100687. doi: 10.1016/j.ajoc.2020.100687. eCollection 2020 Jun.
7
Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration.
Am J Ophthalmol Case Rep. 2020 Mar 31;18:100680. doi: 10.1016/j.ajoc.2020.100680. eCollection 2020 Jun.
8
Brolucizumab and immunogenicity.
Eye (Lond). 2020 Oct;34(10):1726-1728. doi: 10.1038/s41433-020-0853-9. Epub 2020 Apr 6.
9
Brolucizimab-leading an era of structural revolution for long-term VEGF suppression.
Eye (Lond). 2020 Apr;34(4):611-613. doi: 10.1038/s41433-019-0583-z. Epub 2019 Sep 19.
10
Brolucizumab: is extended VEGF suppression on the horizon?
Eye (Lond). 2020 Mar;34(3):424-426. doi: 10.1038/s41433-019-0582-0. Epub 2019 Sep 16.
Zotero 插件